BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Mountain Standard Time
BEGIN:STANDARD
DTSTART:20231102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Mountain Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20230301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Mountain Daylight Time
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:RSVP Here\n\n\nDate : Feb 20\nPlace: Fulginiti Pavilion\nTime 5
-7pm\nSpeaker: David C. Swinney\, PhD\nChief Executive Officer \;\niRN
D3\n\nLearn more about Dr. Swinney in this interview.\nDr. Swinney is co-f
ounder of \;iRND3 \;and has over 20 years broad experience with Sy
ntex and Roche as a leader in pre-clinical drug discovery\, primarily in t
he inflammation and virology disease areas. His previous position was Dire
ctor of Virology Biochemical Pharmacology at Roche Palo Alto. Dr. Swinney
has devoted the majority of his career to the identification of tractable
drug targets\, effective mechanisms of drug action\, and promising leads a
nd clinical candidates to address unmet medical needs. He has also develop
ed an expertise in the understanding and application of binding kinetics o
f drug discovery. Dr. Swinney has a PhD in medicinal chemistry from the Un
iversity of Washington and is author of over 100 publications in the field
s of biochemistry and pharmacology.\n\n\n\n\n\n a.CUI:link\, a.CUI:visi
ted {\n background: #cfb87c\;\n border: none\;\n color: black\;\n
min-width: 300px\;\n padding: 15px 32px\;\n max-width: 300px\;\n
text-align: center\;\n text-decoration: none\;\n display: inline
-block\;\n font-size: 16px\;\n font-weitght: 400\;\n font-family:
Helvetica\, Arial\, sans-serif\;\n margin: 4px 2px\;\n cursor: poin
ter\;\n border-radius: 4px\;\n -webkit-transition-duration: 0.4s\; /
* Safari */\n transition-duration: 0.4s\;\n }\n a.CUI:hover\, a.C
UI:active {\n box-shadow: 0 12px 16px 0 rgba(0\,0\,0\,0.24)\,0 17px 50p
x 0 rgba(0\,0\,0\,0.19)\;\n }\n a:hover {\n cursor:pointer\;\n
}\n
DTEND:20190221T020000Z
DTSTAMP:20240329T072846Z
DTSTART:20190221T000000Z
LOCATION:
SEQUENCE:0
SUMMARY:SPARK 15: The role of molecular mechanism of action in drug discove
ry strategies
UID:RFCALITEM638472725264395181
X-ALT-DESC;FMTTYPE=text/html:RSVP Here\n
\n
\n
Date : Feb 20
\nPlac
e: Fulginiti Pavilion
\nTime 5-7pm
Speaker: David C.
Swinney\, PhD
\nChief Executive Officer \;
\niRND3
\n
\nLearn more about Dr. Swinney in this interview.
Dr. Swinney is co-founder of \;iRND3&
nbsp\;and has over 20 years broad experience with Syntex and Roche as a le
ader in pre-clinical drug discovery\, primarily in the inflammation and vi
rology disease areas. His previous position was Director of Virology Bioch
emical Pharmacology at Roche Palo Alto. Dr. Swinney has devoted the majori
ty of his career to the identification of tractable drug targets\, effecti
ve mechanisms of drug action\, and promising leads and clinical candidates
to address unmet medical needs. He has also developed an expertise in the
understanding and application of binding kinetics of drug discovery. Dr.
Swinney has a PhD in medicinal chemistry from the University of Washington
and is author of over 100 publications in the fields of biochemistry and
pharmacology.
\n
\n
\n